1. Headline
  1. Headline
By
updated 4/18/2011 10:29:24 AM ET 2011-04-18T14:29:24

Researchers are stopping a study that tests a daily pill to prevent infection with the AIDS virus in thousands of African women because partial results show no signs that the drug is doing any good.

  1. More from TODAY.com
    1. 'She was all over me!' Regis dishes on what it was like co-hosting with Kathie Lee

      Today's TrydayFriday was a laugh-out-loud, fun-filled show as Kathie Lee invited her old pal Regis to guest co-host for Ho...

    2. 7 things we learned about Julia Roberts ... 7 years after her last visit to TODAY
    3. Baby boy doll with realistic-looking penis shocks some parents
    4. From 'Face Balls' to foot fetishes: The weirdest moments in TODAY's Take
    5. From soda to negative talk: Join TODAY for a #30DayDetox of bad habits

Women taking Truvada, made by Gilead Sciences Inc., are just as likely to get HIV as other women who have been given dummy pills, an interim analysis of the study found. Even if the study were to continue, it would not be able to determine whether the pills help prevent infection, since the results are even this far along, researchers said.

The finding is disappointing because another study last fall concluded that Truvada did help prevent infections in gay and bisexual men when given with condoms, counseling and other prevention services. Many AIDS experts view that as a breakthrough that might help slow the epidemic.

Family Health International, a nonprofit involved in AIDS research, announced the new results on Monday. The group launched the study two years ago and had enrolled about half of the 3,900 women intended in Kenya, Tanzania and South Africa. As of last week, 56 new HIV infections had occurred, half in each group.

No safety problems were seen with Truvada. However, women taking it were more likely to become pregnant than those on dummy pills.

"That's both a surprising finding and one that we can't readily explain" by what is known so far about Truvada's effects on women using hormonal contraceptives, said Dr. Timothy Mastro of Family Health International. The study was sponsored by the U.S. Agency for International Development and the Bill & Melinda Gates Foundation. Gilead provided the drugs for the study.

Truvada already is sold for treating HIV. It's a combination of two drugs, tenofovir and emtricitabine, or FTC, made by California-based Gilead Sciences Inc.

Using it or its components for prevention is still "very promising," Mastro said, although benefits and risks may vary by gender and by the way the virus is spread — sex between men and women or riskier anal sex among men, for example.

Last year, a study in South Africa found that a vaginal gel spiked with tenofovir cut in half a woman's chances of getting HIV from an infected partner. Protection was greater for those who used it most faithfully.

A similar effect was seen in the study of Truvada in gay men. The drug lowered the chances of infection by 44 percent, and by 73 percent or more among men who took their pills most faithfully. The U.S. Centers for Disease Control and Prevention recently gave advice to doctors on prescribing Truvada along with other prevention services for gay men, based on those encouraging results.

In the new study, "it's difficult to understand why they did not see protection," but blood samples may tell more about whether it's related to how faithfully women took the pills, said Dr. Robert M. Grant of the Gladstone Institutes, a private foundation affiliated with the University of California, San Francisco.

He led the study of Truvada in gay men and said, "we are very confident that this approach is useful" for them.

The new study's result "must be seen as what it is — the closure of a single trial in a field that has generated exciting results in the recent past," said Mitchell Warren, head of the AIDS Vaccine Advocacy Coalition, a nonprofit group that works on HIV prevention research.

Two other large studies testing AIDS drugs for prevention are under way in Africa, in heterosexual women and in couples where one has the virus and the other does not. Results are expected within two years. The studies have mostly been in countries with high rates of new infections because that makes it easier to see whether a prevention measure is having an impact.

Truvada costs $5,000 to $14,000 a year in the United States, but as little as $140 a year in some poor countries where it's available in generic form.

Copyright 2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

More on TODAY.com

  1. ‘She was all over me!' Regis dishes on co-hosting with Kathie Lee

    TrydayFriday was a laugh-out-loud, fun-filled show as KLG invited her old pal to co-host.

    8/1/2014 2:01:46 PM +00:00 2014-08-01T14:01:46
  2. 6 GIFs show why this animal segment is the best one ever

    When animals visit Kathie Lee and Hoda, things always get interesting. But when Regis is co-hosting, it gets down right outrageous!"Does Hoda have a pith helmet here I can put on?

    8/1/2014 2:40:51 PM +00:00 2014-08-01T14:40:51
  3. TODAY the musical! KLG puts together show featuring anchors

    The special Friday edition of TODAY's Fourth Hour was full of surprises — not only did Regis Philbin fill in for Hoda, but Kathie Lee made a big announcement: Get ready for TODAY the musical! "It's going to be live and it's going to be so much fun," an excited Kathie Lee said.

    8/1/2014 2:14:15 PM +00:00 2014-08-01T14:14:15
  4. TODAY
  1. US scrambles to retrieve Ebola-infected Americans

    Health officials are trying to get at least one American patient infected with Ebola virus back from West Africa for treatment. Emory University Hospital said it was ready to take care of one patient at a special isolation unit.

    8/1/2014 3:47:06 PM +00:00 2014-08-01T15:47:06